Mepsevii
What Mepsevii is used for
Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Mepsevii
- Active substance
- vestronidase alfa
- Disease area
- Mucopolysaccharidosis VII
- Medicine group
- Enzymes
- ATC code
- A16AB18
- Marketing authorisation holder
- Ultragenyx Germany GmbH
- Authorised in the EU since
- 2018
Official information
In the USA
Same active substance: Mepsevii
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Mepsevii used for?
Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).
What is the active substance in Mepsevii?
Mepsevii contains vestronidase alfa.
Who makes Mepsevii?
The EU marketing authorisation holder is Ultragenyx Germany GmbH.
Is Mepsevii an orphan medicine?
Yes. Mepsevii is designated an orphan medicine in the EU, for a rare disease (Mucopolysaccharidosis VII).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU